The Latest Cardiac and Vascular News
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2020 on November 13, 2020 Enrollment Completed in […]
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA® (icosapent ethyl) Approval and Commercialization in Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the […]
TORRANCE, Calif., Nov. 5, 2020 /PRNewswire/ — HeartValveSurgery.com, a leading patient advocacy group for patients with heart valve disease, today released results of a new survey finding that most heart valve patients are “not very aware” of clinical trials, but most patients would consider enrolling in a clinical trial. The nationwide survey was […]
2020 Q3 HIGHLIGHTS compared to Q2 2020: – Revenues were $10,727,000, an increase of $4,354,000, or 68%, compared to $6,373,000 – Pre-tax net income of $5,595,000, an increase of $4,605,000, or 465%, compared to $990,000 – Net income was $4,866,000, or $0.74 per basic share and $0.61 per diluted share, […]
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for […]
The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) has been […]
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP EPS were $2.79. FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — […]
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded […]
NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ — Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which […]
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI […]
